Clinical trials: Stage IV Breast Cancer
Breast Neoplasms
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.
- Trial name
- NCT00097721
- Testing
- E7389
- Where
- 16 sites in United States
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Breast Cancer
Bexarotene in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have…
- Trial name
- NCT00003752
- Testing
- bexarotene
- Where
- 30 sites in United States
- Volunteers
- 180 people
- Sponsor
- Ligand Pharmaceuticals
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Metastasis
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer.
- Trial name
- NCT00241449
- Testing
- Fulvestrant, Tamoxifen
- Where
- 139 sites in United States, Argentina and 24 more
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Breast Carcinoma
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
The purpose of this study is to examine the safety and efficacy of Ruxolitinib in combination with Trastuzumab in treatment of HER2 positive metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
- Trial name
- NCT02066532
- Testing
- Ruxolitinib, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dawn L. Hershman
Breast Cancer
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Inserting the p53 gene into the tumor may increase the effectiveness of a chemotherapy drug by making tumor…
- Trial name
- NCT00044993
- Testing
- Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Introgen Therapeutics
Breast Cancer
HER-2 Protein Vaccine in Treating Women With Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women who have breast cancer.
- Trial name
- NCT00068614
- Testing
- HER-2/neu peptide vaccine
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Breast Cancer
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
The objective of this phase II study is to evaluate efficacy and safety of avastin plus modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients. Fifty-five patients will be enrolled into this study.
- Trial name
- NCT01658033
- Testing
- Avastin + mFOLFOX6
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and…
- Trial name
- NCT03184558
- Testing
- Bemcentinib; pembrolizumab
- Where
- 17 sites in United States, Norway and 2 more
- Volunteers
- 29 people
- Sponsor
- BerGenBio ASA
Breast Cancer
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed.
- Trial name
- NCT00002826
- Testing
- paclitaxel, valspodar
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Breast Cancer, HER2-positive Breast Cancer
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
Heroes is a multicentre, national, non-randomized, open-label, phase 2 study. The goal of this clinical trial is to evaluate the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer with disease…
- Trial name
- HEROES (NCT06450314)
- Testing
- Discontinuation of the anti-HER2 maintenance therapy, Monitoring with signatera test
- Where
- France
- Volunteers
- 170 people
- Sponsor
- UNICANCER
Breast Cancer Metastatic, Breast Carcinoma
Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer
Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to…
- Trial name
- NCT07003009
- Testing
- Malign Lymph Node Washout, Benign Lymph Node Washout
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Training and Research Hospital
Breast Cancer
Metabolomics Explores Biomarkers for Metastatic Breast Cancer
RATIONALE: Studying samples of plasm by metabolomics-based approach from women with metastasis breast cancer may help doctors understand the biomarker of visceral metastasis.
- Trial name
- NCT04302415
- Testing
- There is no other intervention, only clinical treatment.
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Breast Cancer, Metastatic Colorectal Cancer
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers
The proposed theory is based on combination of radiation therapy with usual targeted therapies capable of ADCC (Antibody-Dependant Cell Cytotoxicity).
- Conditions
- Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer
- Trial name
- IRAM (NCT03323424)
- Testing
- Systemic treatment + Stereotactic Body Radio-Therapy (SBRT), Systemic treatment
- Where
- 6 sites in France
- Sponsor
- Institut de Cancérologie de la Loire
Breast Cancer
Gene Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Placing the gene for interleukin-12 into breast cancer cells may help the body build an immune response to kill tumor cells.
- Trial name
- NCT00849459
- Testing
- adenovirus-mediated human interleukin-12
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Max Sung
Breast Cancer Metastatic
Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer
Primary Objectives: To assess the safety for each cohort of patients on a fixed-dose combination pill of capecitabine and cyclophosphamide administered at flat dose and with metronomic schedule (defined as continuous daily…
- Trial name
- METRO-ABC (NCT02664103)
- Testing
- Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
- Where
- 5 sites in India
- Volunteers
- 2 people
- Sponsor
- Sanofi
Breast Cancer
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may kill more tumor cells.
- Trial name
- NCT00002680
- Testing
- filgrastim, cyclophosphamide, megestrol acetate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Locally Advanced or Metastatic Breast Cancer
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with…
- Trial name
- CAPItana (NCT06764186)
- Testing
- Fulvestrant, Capivasertib
- Where
- 17 sites in Spain
- Volunteers
- 101 people
- Sponsor
- AstraZeneca